Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Healthcare Triangle (HCTI) EBITDA (2020 - 2025)

Healthcare Triangle filings provide 6 years of EBITDA readings, the most recent being -$4.5 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 48.79% to -$4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$9.1 million, a 30.22% increase, with the full-year FY2025 number at -$9.5 million, up 29.39% from a year prior.
  • EBITDA reached -$4.5 million in Q4 2025 per HCTI's latest filing, down from -$1.9 million in the prior quarter.
  • The five-year high for EBITDA was $470000.0 in Q2 2021, with the low at -$10.6 million in Q4 2022.
  • A 5-year average of -$2.6 million and a median of -$1.7 million in 2023 define the central range for EBITDA.
  • Year-over-year, EBITDA plummeted 1024.68% in 2021 and then skyrocketed 87.48% in 2023.
  • Year by year, EBITDA stood at -$3.3 million in 2021, then tumbled by 220.09% to -$10.6 million in 2022, then skyrocketed by 87.48% to -$1.3 million in 2023, then crashed by 559.38% to -$8.8 million in 2024, then skyrocketed by 48.79% to -$4.5 million in 2025.
  • Per Business Quant, the three most recent readings for HCTI's EBITDA are -$4.5 million (Q4 2025), -$1.9 million (Q3 2025), and -$1.4 million (Q2 2025).